DOCSLIB.ORG

Inhibitors, Activators, Enzymes, Receptors

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Inhibitors, Activators, Enzymes, Receptors Inhibitors, Activators, Enzymes, Receptors We declare that some of the listed products might be protected by valid patents. They are only for scientific research and development purpose. They are not offered for sales in countries where the sales of such products constitutes patents infringement. The liability for patents checking and patents infringement is exclusive at buyers risk! I2CNS LLC CANNOT BE HELD LIABLE FOR ANY VIOLATIONS OF PATENT RIGHTS CAUSED BY CUSTOMERS. CAS No. Name Formula 208260-29-1 ZM336372 912356-08-2 (3aR,12bR)-rel-5-Chloro- 2,3,3a,12b-tetrahydro-2-methyl- 1H-dibenz[2,3:6,7]oxepino[4,5- c]pyrrol-1-one 1030612-87-3 (5-{5-[4-(2-bromo-5- fluorophenoxy)piperidin-1-yl]- [1,3,4]-thiadiazol-2-yl}-2H- tetrazol-2-yl)acetic acid 618430-24-3 (R)-tert-butyl 1-(3-benzyl-7- chloro-4-oxo-4H-chromen-2- yl)-2-methylpropylcarbamate 1012104-68-5 1-((1r,4r)-4-hydroxycyclohexyl)- N-isopentyl-2-(5-(2- (trifluoromethoxy)phenyl)-1H- indazol-3-ylamino)- 19685-09-7 10-hydroxycamptothecin 19608-29-8 17 alpha-propionate 133-32-4 3-Indolebutyric acid 1144080-31-8 4,6-Dichloro-1-(1,4- dioxaspiro[4.5]dec-8-yl)-1H- pyrazolo[3,4-d]pyrimidine 4-(4-Fluoro-1-naphthalenyl)-6- (1-methylethyl)-2- pyrimidinamine maleate 226907-52-4 6-amino-9-benzyl-2-(2- methoxyethoxy)-9H-purin-8-ol 154-42-7 6-Thioguanine 86639-52-3 7-Ethyl-10- hydroxycamptothecin 272438-84-3 7H-Pyrrolo[1,2-c]imidazol-7-one 959122-11-3 A 922500 552325-73-2 A-674563 844499-71-4 A-769662/A769662 934162-61-5 A-966492/A966492 1345973-49-0 AB-001 154229-19-3 Abiraterone(CB-7598) 923564-51-6 ABT-263(Navitoclax) 796967-16-3 ABT-869(Linifanib)/AL- 39324,RG3635 912444-00-9 ABT-888(Veliparib) 852808-04-9 ABT737/ABT-737 950769-58-1 AC220 114607-46-4 Acitazanolast 55079-83-9 Acitretin 850173-95-4 ADL-5859 51-21-8 Adrucil(Fluorouracil) 497839-62-0 AEE788 459868-92-9 AG-014699 ，Rucaparib 170449-18-0， AG-1478 153436-53-4 133550-30-8 AG-490 328543-09-5 AG14361/AG-14361 138112-76-2 Agomelatine 55154-30-8 AH7921 473382-39-7 Akt-l-1 173334-57-1 Aliskiren 871224-64-5 Almorexant 164178-33-0 AM 630 335161-24-5 AM-2201/AM2201 444912-75-8 AM2233 364782-34-3 AMG-073 (Cinacalcet hydrochloride) 1002304-34-8 AMG-208 882663-88-9 AMG-47a 453562-69-1 AMG-706(Motesanib) 870223-96-4 AMG-Tie2-1 913376-83-7 AMG458/AMG-458 125316-60-1 AMG580 945595-80-2 AMG900 71675-85-9 Amisulpride 88150-42-9 Amlodipine 875446-37-0 Anacetrapib ，MK-0859 401900-40-1 Andarine 72432-10-1 Aniracetam 828934-41-4 ANTI-EAPII (TTRAP) 943319-70-8 AP24534(Ponatinib) 503612-47-3 Apixaban 170729-80-3 Aprepitant(MK-0869) 935881-37-1 AR-42 (HDAC-42) 121032-29-9 Arranon 937265-83-3 ARRY380 69408-81-7 AS-1413(Amonafide) 648449-76-7 AS-604850 648450-29-7 AS-605240 900515-16-4 AS252424;AS-252424 65576-45-6 Asenapine 902135-89-1 AT 7519 mesylate 902135-91-5 AT-7519(HCI) 844442-38-2 AT7519 857531-00-1 AT7867/AT-7867 896466-76- AT9283 5;896466-04-9 198904-31-3， Atazanavir(BMS-232632) 229975-97-7 1158838-45-9 Aurora A Inhibitor I 475108-18-0 AV-951(Tivozanib) 166518-60-1 Avasimibe(CI-1011) 319460-85-0 Axitinib 878739-06-1 AZ 628 915720-21-7 AZ-23 905586-69-8 AZ-960 ，AZ960 1124329-14-1 AZ3146 448-34-0 Azaprocin 602306-29-6 AZD 5438 606143-52-6 AZD- 6244(Selumetinib)/AZD6244 1173900-33-8 AZD-6482/AZD6482 860352-01-8 AZD-7762 848942-61-0 AZD-8931 379231-04-6 AZD0530 722544-51-6 AZD1152-HQPA(Barasertib) 935666-88-9 AZD1480 763113-22- AZD2281(olaparib)/AZD-2281 0(937799-91-2) AZD4547/AZD-4547 1009298-09-2 AZD8055 ，AZD-8055 869357-68-6 AZD8330/ARRY-424704/arry- 704/AZD8330/AZD-8330 123524-52-7 Azelnidipine 887650-05-7 Bafetinib 853910-02-8 BAG956 475150-69-7 BAN ORL 24HCL 755037-03-7 BAY73-4506(Regorafenib) 414864-00-9 Belinostat/PXD101,PX105684 162220-36-2 Bencynoate hydrochloride 501437-28-1 BI-D1870 755038-02-9 BI2536/BI-2536 755038-65-4 BI6727 (Volasertib) 120410-24-4 Biapenem 928326-83-4 BIBF1120,BIBF-1120,Vargatef 321674-73-1 BIBR-1532 439081-18-2 BIBW2992 848695-25-0 BIIB021 155206-00-1 Bimatoprost 1235-82-1 Biperiden hydrochloride 285983-48-4 BIRB 796(Doramapimod) 66722-44-9 Bisoprolol 104344-23-2 Bisoprolol Fumarate 1094614-85-3 BIX 02189 1094614-84-2 BIX02188 11056-06-7 Bleomycin hcl 2854-32-2 BML 190 n/a BMS-265246 468740-43-4 BMS-536924 8173837-23-1 BMS-599626 1146699-66-2 BMS-708163 1001350-96-4 BMS-754807 1196681-44-3 BMS-777607/BMS777607 BMS-903710 859853-30-8 BMS690514/BMS-690514 729607-74-3 BMS707035/BMS-707035 21102-95-4 BMY7378,BMY-7378 dihydrochloride 361442-00-4 Boc-3-Hydroxy-1-adamantyl-D- glycine 394730-60-0 Boceprevir/EBP520/Sch503034 179324-69-7 Bortezomib 380843-75-4 Bosutinib(SKI-606) 649735-63-7 Brivanib alaninate/BMS-582664 649735-46-6 Brivanib(BMS-540215) 57477-39-1 BRL 54443 160003-66-7 BSI-201/Iniparib 64872-77-1 Butoconazole nitrate 183133-96-2 Cabazitaxel 849217-68-1 Cabozantinib 870281-82-6 CAL101,CAL-101 19356-17-3 Calcifediol 112828-00-9 Calcipotriol 32222-06-3 Calcitriol 842133-18-0 Canagliflozin 56689-43-1 Canbisol 267543-28-7 Canertinib 289499-45-2 Canertinib dihydrochloride(CI 1033) 154361-50-9 Capecitabine(Xeloda) 587881-33-2 Carbamic acid 147568-66-9 Carmoterol 1218777-13-9 CAY10505 395104-30-0 CC-401 942947-93-5 CCT129202 1095382-05-0 CCT137690 102121-60-8 CD437 288383-20-0 cedirannib (557795-03-6) 88040-23-7 Cefepime(Maxipime) 169590-42-5 Celecoxib 124182-57-6 CGS-21680/CGS21680 918659-56-0 Chaetominine 405169-16- CHIR-258(Dovitinib) 6,852433-84-2 252917-06-9 CHIR99021(CT99021) 267243-28-7 CI-1033(Canertinib) 212631-79-3 CI-1040 112522-64-2 CI994 153259-65-5 Cilomilast(SB-207499) 15663-27-1 Cisplatin 168555-66-6 Combretastatin A4 disodium phosphate 1080622-86-1 CP-466722 383432-38- CP-724714 0;537705-08-1 477600-75-2 CP690550(Tasocitinib) 670220-88-9 CP868569 1012054-59-9 CUDC-101 865311-47-3 CX-3543 1009820-21-6 CX-4945 1138549-36-6 CX-5461/CX5461 693228-63-6 CYC-116 294-90-6 Cyclen 4449-51-8 Cyclopamine 1056634-68-4 CYT387 917111-44-5 CYT997 211915-06-9 Dabigatran etexilate 1009119-64-5， Daclatasvir (BMS-790052) 1214735-16-6 211513-37-0 Dalcetrapib(JTT-705),JTT705 850876-88-9 Danoprevir(ITMN-191) 827318-97-8 Danusertib(PHA-739358) 461432-26-8 Dapagliflozin(BMS-512148) 208255-80-5 DAPT 302962-49-8， Dasatinib 863127-77-9 23541-50-6 Daunorubicin hydrochloride 572924-54-0 Deforolimus 100643-71-8 Desloratadine 53-43-0 DHEA 67165-56-4 Diclofensine ；Ro 8-4650 660-27-5 Diisopropylammonium dichloroacetate 3613-73-8 Dimebon 58-32-2 Dipyridamole 157341-41-8 DMP-777 117570-53-3 DMXAA(ASA404) 125354-16-7 Docetaxel 148408-66-6 Docetaxel trihydrate 114977-28-5 Docetaxel(Taxotere) 1051375-16-6 dolutegravir/GSK1349572/S- 349572 120011-70-3 Donepezil hydrochloride 364622-82-2 Doripenem Hydrate/Doribax/S- 4661/Finibax 54573-75-0 Doxercalciferol 67392-87-4 Drospirenone 164656-23-9 Dutasteride 417716-92-8 E7080 89-25-8 Edaravone 154598-52-4 Efavirenz 496775-61-2 Eltrombopag 697761-98-1 Elvitegravir,EVG,GS- 9137,JTK-303 170364-57-5 enzastaurin 152044-54-7 Epothilone B 133040-01-4 Eprosartan 183319-69-9， Erlotinib hydrochloride 183321-74-6 (Synonyms CP-358774, OSI- 774, NSC 718781) 159351-69-6 Everolimus(RAD001) Exatecan mesilate 849217-64-7 EXEL-2880 300657-03-8 FABP4 Inhibitor 105628-07-7 Fasudil hydrochloride 144060-53-7 Febuxostat(Uloric) 73151-29-8 Fenticonazole nitrate 286930-03-8 Fesoterodine fumarate 808118-40-3 FG-4592/FG4592 104987-11-3 FK-506 146426-40-6 Flavopiridol(Alvocidib) 21679-14-1 Fludarabine 901119-35-5 Fostamatinib;R788 162359-56-0 FTY720 194804-75-6， Garenoxacin 223652-90-2 76778-22-8 GBR-12935 879085-55-9 GDC-0449(Vismodegib) 905281-76-7 GDC-0879,GDC0879 957054-30-7 GDC-0941 1032754-93-0 GDC0980 184475-35-2 Gefitinib 30562-34-6 Geldanamycin 122111-03-9 Gemcitabine Hydrochloride 871700-17-3 GSK-1120212/GSK1120212 958852-01-1 GSK1059615 942918-07-2 GSK1070916 1032823-75-8 GSK1292263 1089283-49-7 GSK1904529A 1086062-66-9 GSK2126458 801312-28-7 GSK256066 GSK369796/GSK-369796 864082-47-3 GSK429286A 929095-18-1 GSK461364 937174-76-0 GSK690693 660868-91-7 GW 843682X 405911-09-3 GW-3965 127243-85-0 H-89 2HCl 660847-06-3 HDAC inhibitor 173529-46-9 HMN-214(IVX-214) 140835-18-3 HU 243 68-96-2 Hydroxyprogesterone 302-23-8 Hydroxyprogesterone acetate 50847-11-5 Ibudilast 371242-69-2 IC-87114;IC87114 847591-62- ICG-001/ICG001 2;780757-88-2 58957-92-9 Idarubicin HCl 133454-47-4 Iloperidone(Fanapt) 152459-95-5 Imatinib 220127-57-1 Imatinib mesylate 1092939-15-5， INCB018424 1092939-16-6 1092939-17-7 INCB018424 941678-49-5 INCB018424(Ruxolitinib) 1029712-80-8 INCB28060 3544-24-9 INO-1001 138402-11-6 Irbesartan(Avapro) 961-29-5 Isoliquiritigenin 336113-53-2 Ispinesib 873054-44-5 Ivacaftor (VX-770) 943540-75-8 JNJ-38877605 443797-96-4 JNJ7706621 244218-51-7 JTC-801/JTC801 182004-65-5 KB-R7943 142273-20-9 Kenpaullone 623142-96-1 Ki20227(+/-) 1283519-40-3 KN-92 127191-97-3 KN62 139298-40-1 KN93 461054-93-3 Ko 143 925701-49-1 KU-60019 938440-64-3 KU0063794(KU63794) 587871-26-9 KU55933 503468-95-9 KU57788/NU7441 203120-17-6 Laninamivir 231277-92-2 Lapatinib 388082-78- Lapatinib Ditosylate 8;388082-77-7 404950-80-7 LBH-589/Panobinostat 1062368-24-4 LDN193189(DM3189) 191732-72-6 Lenalidomide 668270-12-0 Linagliptin 192725-17-0 Lopinavir 114798-26-4 Losartan 1033805-22-9 LX1606 LX7101 Hydrochloride 154447-36-6 LY 294002 700874-72-2 LY-2157299 635318-11-5 LY2140023/LY404039 862505-00-8 LY2228820 862507-23-1 LY2228820/LY-2228820 LY2322600 911222-45-2 LY2603618 (IC-83) 1234703-40-2 LY2608204 LY2779357 1229236-86-5 LY2784544/LY-2784544 1194044-20-6 LY2811376 LY2814617 1262036-50-9 LY2886721/LY-2886721 1258861-20-9 LY2940680 LY2979165-Ammonimum salt LY3006072 192927-92-7 LY310762 hydrochloride 172732-68-2 LY315920(Varespladib) 201943-63-7
Load more

Recommended publications
  • Régulation De L'inflammation Par Les Lipides Bioactifs : Interactions Biosynthétiques Et Fonctionnelles Entre Les Endocannabinoïdes Et Les Éicosanoïdes
    Régulation de l'inflammation par les lipides bioactifs : interactions biosynthétiques et fonctionnelles entre les endocannabinoïdes et les éicosanoïdes Thèse Caroline Turcotte Doctorat en microbiologie-immunologie Philosophiæ doctor (Ph. D.) Québec, Canada © Caroline Turcotte, 2019 Régulation de l’inflammation par les lipides bioactifs : interactions biosynthétiques et fonctionnelles entre les endocannabinoïdes et les éicosanoïdes Thèse Caroline Turcotte Sous la direction de : Nicolas Flamand, directeur de recherche Marie-Renée Blanchet, codirectrice de recherche Résumé Les maladies inflammatoires chroniques sont un fardeau de santé important à travers le monde. Les traitements actuellement disponibles soulagent la douleur et l’inflammation, mais leurs effets secondaires rendent leur utilisation à long terme risquée. À la lumière de cette problématique, la communauté scientifique s’intéresse au potentiel d’anti-inflammatoires naturels comme les endocannabinoïdes. Les endocannabinoïdes sont des lipides endogènes qui activent les récepteurs cannabinoïdes (CB1 et CB2). Ils régulent ainsi divers processus physiologiques tels l’appétit, l’adipogénèse et la nociception. Les deux endocannabinoïdes les mieux caractérisés, le 2-AG et l’AEA, peuvent également moduler l’inflammation en activant le récepteur CB2 à la surface des cellules immunitaires. Les souris déficientes pour le récepteur CB2 présentent un phénotype inflammatoire exacerbé, suggérant que ce récepteur est anti-inflammatoire. Cependant, le rôle des endocannabinoïdes dans l’inflammation est beaucoup plus complexe puisqu’ils peuvent être métabolisés en une grande variété de médiateurs lipidiques de l’inflammation. Leur voie de dégradation principale est leur hydrolyse en acide arachidonique (AA), qui sert de précurseur à la biosynthèse d’éicosanoïdes pro-inflammatoires comme le leucotriène B4 et la prostaglandine E2. Ils peuvent également être métabolisés directement par certaines enzymes impliquées dans la synthèse d’éicosanoïdes, pour générer des médiateurs comme les prostaglandines-glycérol (PG-G).
    [Show full text]
  • Regulation of Brain Reward by the Endocannabinoid System: a Critical Review of Behavioral Studies in Animals
    Send Orders for Reprints to [email protected] Current Pharmaceutical Design, 2014, 20, 000-000 1 Regulation of Brain Reward by the Endocannabinoid System: A Critical Review of Behavioral Studies in Animals S. Vlachou2 and G. Panagis1,* 1Laboratory of Behavioral Neuroscience, Department of Psychology, School of Social Sciences, University of Crete, 74100 Rethym- non, Crete, Greece; 2School of Nursing and Human Sciences, Faculty of Science and Health, Dublin City University, Glasnevin, Dub- lin 9, Ireland Abstract: The endocannabinoid system has been implicated in the regulation of a variety of physiological processes, including a crucial involvement in brain reward systems and the regulation of motivational processes. Behavioral studies have shown that cannabinoid re- ward may involve the same brain circuits and similar brain mechanisms with other drugs of abuse, such as nicotine, cocaine, alcohol and heroin, as well as natural rewards, such as food, water and sucrose, although the conditions under which cannabinoids exert their reward- ing effects may be more limited. The purpose of the present review is to briefly describe and evaluate the behavioral and pharmacological research concerning the major components of the endocannabinoid system and reward processes. Special emphasis is placed on data re- ceived from four procedures used to test the effects of the endocannabinoid system on brain reward in animals; namely, the intracranial self-stimulation paradigm, the self-administration procedure, the conditioned place preference procedure and the drug-discrimination pro- cedure. The effects of cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptor agonists, antagonists and endocannabinoid modulators in these procedures are examined. Further, the involvement of CB1 and CB2 receptors, as well the fatty acid amid hydrolase (FAAH) en- zyme in reward processes is investigated through presentation of respective genetic ablation studies in mice.
    [Show full text]
  • Alcohol and Drug Abuse Subchapter 9
    Chapter 8 – Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority This rule is established under the authority of 18 V.S.A. §§ 4201 and 4202 which authorizes the Vermont Board of Health to designate regulated drugs for the protection of public health and safety. 2.0 Purpose This rule designates drugs and other chemical substances that are illegal or judged to be potentially fatal or harmful for human consumption unless prescribed and dispensed by a professional licensed to prescribe or dispense them and used in accordance with the prescription. The rule restricts the possession of certain drugs above a specified quantity. The rule also establishes benchmark unlawful dosages for certain drugs to provide a baseline for use by prosecutors to seek enhanced penalties for possession of higher quantities of the drug in accordance with multipliers found at 18 V.S.A. § 4234. 3.0 Definitions 3.1 “Analog” means one of a group of chemical components similar in structure but different with respect to elemental composition. It can differ in one or more atoms, functional groups or substructures, which are replaced with other atoms, groups or substructures. 3.2 “Benchmark Unlawful Dosage” means the quantity of a drug commonly consumed over a twenty-four-hour period for any therapeutic purpose, as established by the manufacturer of the drug. Benchmark Unlawful dosage is not a medical or pharmacologic concept with any implication for medical practice. Instead, it is a legal concept established only for the purpose of calculating penalties for improper sale, possession, or dispensing of drugs pursuant to 18 V.S.A.
    [Show full text]
  • Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority
    Chapter 8 – Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority This rule is established under the authority of 18 V.S.A. §§ 4201 and 4202 which authorizes the Vermont Board of Health to designate regulated drugs for the protection of public health and safety. 2.0 Purpose This rule designates drugs and other chemical substances that are illegal or judged to be potentially fatal or harmful for human consumption unless prescribed and dispensed by a professional licensed to prescribe or dispense them, and used in accordance with the prescription. The rule restricts the possession of certain drugs above a specified quantity. The rule also establishes benchmark unlawful dosages for certain drugs to provide a baseline for use by prosecutors to seek enhanced penalties for possession of higher quantities of the drug in accordance with multipliers found at 18 V.S.A. § 4234. 3.0 Definitions 3.1 “Analog” means one of a group of chemical components similar in structure but different with respect to elemental composition. It can differ in one or more atoms, functional groups or substructures, which are replaced with other atoms, groups or substructures. 3.2 “Benchmark Unlawful Dosage” means the quantity of a drug commonly consumed over a twenty-four hour period for any therapeutic purpose, as established by the manufacturer of the drug. Benchmark Unlawful dosage is not a medical or pharmacologic concept with any implication for medical practice. Instead, it is a legal concept established only for the purpose of calculating penalties for improper sale, possession, or dispensing of drugs pursuant to 18 V.S.A.
    [Show full text]
  • Cannabinoid Modulation of Reinforcement Maintained by Stimulation of the Medial Forebrain Bundle in C57bl/6J Mice
    Virginia Commonwealth University VCU Scholars Compass Theses and Dissertations Graduate School 2013 Cannabinoid Modulation of Reinforcement Maintained by Stimulation of the Medial Forebrain Bundle in C57Bl/6J Mice Jason Wiebelhaus Virginia Commonwealth University Follow this and additional works at: https://scholarscompass.vcu.edu/etd Part of the Psychology Commons © The Author Downloaded from https://scholarscompass.vcu.edu/etd/555 This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. © Jason Michael Wiebelhaus, 2013 All Rights Reserved Cannabinoid Modulation of Reinforcement Maintained by Stimulation of the Medial Forebrain Bundle in C57Bl/6J Mice Dissertation to be submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy at Virginia Commonwealth University By: Jason M. Wiebelhaus Master of Science, Virginia Commonwealth University, 2009 Bachelor of Science, University of WI-Eau Claire, 2006 Co-Directors: Aron H. Lichtman1, Ph.D. and Joseph H. Porter2, Ph.D. 1, 2Professors 1Department of Pharmacology and Toxicology, 2Department of Psychology Virginia Commonwealth University Richmond, VA September, 2013 ii Acknowledgement I owe my thanks to many people who helped me throughout the process of conducting these experiments and writing my dissertation. First and foremost I would like to thank my mentor and dissertation co-director director Aron H. Lichtman for his guidance and patience throughout my years of graduate school at Virginia Commonwealth University. I would also like to thank my committee members Joseph H.
    [Show full text]
  • Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for ADD
    Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for ADD Chemical Activity Count (+)-ALPHA-VINIFERIN 1 (+)-AROMOLINE 1 (+)-BORNYL-ISOVALERATE 1 (+)-CATECHIN 4 (+)-CEPHARANTHINE 1 (+)-EUDESMA-4(14),7(11)-DIENE-3-ONE 1 (+)-GALLOCATECHIN 1 (+)-HERNANDEZINE 2 (+)-ISOLARICIRESINOL 1 (+)-NORTRACHELOGENIN 1 (+)-PRAERUPTORUM-A 1 (+)-PSEUDOEPHEDRINE 1 (+)-SYRINGARESINOL 1 (+)-SYRINGARESINOL-DI-O-BETA-D-GLUCOSIDE 1 (+)-T-CADINOL 1 (+)-TENUIPINE 1 (+)-TETRANDRINE 1 (-)-16,17-DIHYDROXY-16BETA-KAURAN-19-OIC 1 (-)-ALPHA-BISABOLOL 1 (-)-APOGLAZIOVINE 2 (-)-BETONICINE 1 (-)-BISPARTHENOLIDINE 1 (-)-BORNYL-CAFFEATE 2 (-)-BORNYL-FERULATE 2 (-)-BORNYL-P-COUMARATE 2 (-)-CANADINE 1 (-)-CURINE 1 Chemical Activity Count (-)-DAURISOLINE 1 (-)-DICENTRINE 1 (-)-EMETINE 1 (-)-EPICATECHIN 3 (-)-EPICATECHIN-3-O-GALLATE 1 (-)-EPIGALLOCATECHIN 2 (-)-EPIGALLOCATECHIN-3-O-GALLATE 1 (-)-EPIGALLOCATECHIN-GALLATE 2 (-)-EUDESMIN 1 (-)-HYDROXYJASMONIC-ACID 1 (-)-IBOGAMINE 1 (-)-STEPHOLIDINE 1 (-)-TENUIPINE 1 (1'S)-1'-ACETOXYCHAVICOL-ACETATE 2 (2R)-(12Z,15Z)-2-HYDROXY-4-OXOHENEICOSA-12,15-DIEN-1-YL-ACETATE 1 (7R,10R)-CAROTA-1,4-DIENALDEHYDE 1 (E)-4-(3',4'-DIMETHOXYPHENYL)-BUT-3-EN-OL 1 1,2,6-TRI-O-GALLOYL-BETA-D-GLUCOSE 1 1,7-BIS(3,4-DIHYDROXYPHENYL)HEPTA-4E,6E-DIEN-3-ONE 1 1,7-BIS-(4-HYDROXYPHENYL)-1,4,6-HEPTATRIEN-3-ONE 1 1,8-CINEOLE 4 1-ETHYL-BETA-CARBOLINE 2 1-HYDROXY-2-(3'-PENTENYL)-3,7-DIMETHYLBENZOFURAN 1 1-METHOXY-2-(3'-PENTENYL)-3,7-DIMETHYLBENZOFURAN 1 1-O-(2,3,4-TRIHYDROXY-3-METHYL)-BUTYL-6-O-FERULOYL-BETA-D-GLUCOPYRANOSIDE 1 10,6-HONOKIOL 1
    [Show full text]
  • Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Epilepsy
    Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Epilepsy Chemical Activity Count (+)-ALPHA-VINIFERIN 1 (+)-BORNYL-ISOVALERATE 1 (+)-CATECHIN 3 (+)-EUDESMA-4(14),7(11)-DIENE-3-ONE 1 (+)-HERNANDEZINE 1 (+)-ISOCORYDINE 1 (+)-PSEUDOEPHEDRINE 1 (+)-SYRINGARESINOL-DI-O-BETA-D-GLUCOSIDE 1 (+)-T-CADINOL 1 (-)-16,17-DIHYDROXY-16BETA-KAURAN-19-OIC 1 (-)-ALPHA-BISABOLOL 2 (-)-ANABASINE 1 (-)-APOGLAZIOVINE 1 (-)-BETONICINE 1 (-)-BORNYL-CAFFEATE 1 (-)-BORNYL-FERULATE 1 (-)-BORNYL-P-COUMARATE 1 (-)-DICENTRINE 2 (-)-EPIAFZELECHIN 1 (-)-EPICATECHIN 1 (-)-EPIGALLOCATECHIN-GALLATE 1 (1'S)-1'-ACETOXYCHAVICOL-ACETATE 1 (15:1)-CARDANOL 1 (E)-4-(3',4'-DIMETHOXYPHENYL)-BUT-3-EN-OL 1 1,7-BIS-(4-HYDROXYPHENYL)-1,4,6-HEPTATRIEN-3-ONE 1 1,8-CINEOLE 4 10-ACETOXY-8-HYDROXY-9-ISOBUTYLOXY-6-METHOXYTHYMOL 1 Chemical Activity Count 10-DEHYDROGINGERDIONE 1 10-GINGERDIONE 1 11-HYDROXY-DELTA-8-THC 1 11-HYDROXY-DELTA-9-THC 1 13',II8-BIAPIGENIN 1 13-OXYINGENOL-ESTER 1 16,17-DIHYDROXY-16BETA-KAURAN-19-OIC 1 16-EPIMETHUENINE 1 16-HYDROXYINGENOL-ESTER 1 2'-O-GLYCOSYLVITEXIN 1 2-BETA,3BETA-27-TRIHYDROXYOLEAN-12-ENE-23,28-DICARBOXYLIC-ACID 1 2-METHYLBUT-3-ENE-2-OL 2 20-DEOXYINGENOL-ESTER 1 22BETA-ESCIN 1 24-METHYLENE-CYCLOARTANOL 1 3,3'-DIMETHYLELLAGIC-ACID 1 3,4-DIMETHOXYTOLUENE 1 3,4-METHYLENE-DIOXYCINNAMIC-ACID-BORNYL-ESTER 2 3,4-SECOTRITERPENE-ACID-20-EPI-KOETJAPIC-ACID 1 3-ACETYLACONITINE 1 3-ACETYLNERBOWDINE 1 3-BETA-HYDROXY-2,3-DIHYDROWITHANOLIDE-F 1 3-HYDROXY-FLAVONE 1 3-N-BUTYL-PHTHALIDE 3 3-O-ACETYLOLEANOLIC-ACID 1 3-OXO-11-ALPHA-HYDROXYOLEAN-12-ENE-30-OIC-ACID
    [Show full text]
  • Analysis of Bio-Molecules for System Level Understanding of Alzheimer’S Disease
    ANALYSIS OF BIO-MOLECULES FOR SYSTEM LEVEL UNDERSTANDING OF ALZHEIMER’S DISEASE By PRIYA PRADAYANI PANIGRAHI A THESIS SUBMITTED IN FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY IN BIOINFORMATICS JAYPEE UNIVERSITY OF INFORMATION TECHNOLOGY WAKNAGHAT OCTOBER, 2014 ACKNOWLEDGEMENTS God gives blessings to us so we can give glory to him. I'm blessed and I thank God for everything in my life. I deem it my privilege and honour to place and record my gratitude and indebtedness to the following without whose support, guidance, and concern I would not have been able to complete my Ph. D thesis. I feel privileged to express my deep sense of reverence and gratitude to my revered mentor, Dr. Tiratha Raj Singh, for his support, immaculate guidance, constructive criticism, constant encouragement and providing requisite facilities to carry on my research which otherwise would have remained incomplete. His nurturing and caring concern has been a stimulus which I will always cherish. I also appreciate his untiring efforts during the entire tenure of my research work and patience during writing of this thesis. I have no words to express my gratitude for everything he has contributed in my Ph. D and without his blessings it was surely impossible for me to finish my work. I thank him from bottom of my heart. I emphatically express my loyal and venerable thanks to Prof. Shiban Kishen Kak (Vice Chancellor, JUIT), Brig. (Retd.) Balbir Singh (Director, JUIT), Prof. T. S.Lamba (Dean, JUIT) and Dr. Y. Medury (Ex-COO, Jaypee Education System) for providing opportunity to pursue a Doctorate Degree, teaching assistantship and advanced lab infrastructure to accomplish this scientific venture of my life.
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]
  • Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
    Molecules 2016, 21, 75; doi:10.3390/molecules21010075 S1 of S110 Supplementary Materials: Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs Fei Mao 1, Wei Ni 1, Xiang Xu 1, Hui Wang 1, Jing Wang 1, Min Ji 1 and Jian Li * Table S1. Common names, indications, CAS Registry Numbers and molecular formulas of 6891 approved drugs. Common Name Indication CAS Number Oral Molecular Formula Abacavir Antiviral 136470-78-5 Y C14H18N6O Abafungin Antifungal 129639-79-8 C21H22N4OS Abamectin Component B1a Anthelminithic 65195-55-3 C48H72O14 Abamectin Component B1b Anthelminithic 65195-56-4 C47H70O14 Abanoquil Adrenergic 90402-40-7 C22H25N3O4 Abaperidone Antipsychotic 183849-43-6 C25H25FN2O5 Abecarnil Anxiolytic 111841-85-1 Y C24H24N2O4 Abiraterone Antineoplastic 154229-19-3 Y C24H31NO Abitesartan Antihypertensive 137882-98-5 C26H31N5O3 Ablukast Bronchodilator 96566-25-5 C28H34O8 Abunidazole Antifungal 91017-58-2 C15H19N3O4 Acadesine Cardiotonic 2627-69-2 Y C9H14N4O5 Acamprosate Alcohol Deterrant 77337-76-9 Y C5H11NO4S Acaprazine Nootropic 55485-20-6 Y C15H21Cl2N3O Acarbose Antidiabetic 56180-94-0 Y C25H43NO18 Acebrochol Steroid 514-50-1 C29H48Br2O2 Acebutolol Antihypertensive 37517-30-9 Y C18H28N2O4 Acecainide Antiarrhythmic 32795-44-1 Y C15H23N3O2 Acecarbromal Sedative 77-66-7 Y C9H15BrN2O3 Aceclidine Cholinergic 827-61-2 C9H15NO2 Aceclofenac Antiinflammatory 89796-99-6 Y C16H13Cl2NO4 Acedapsone Antibiotic 77-46-3 C16H16N2O4S Acediasulfone Sodium Antibiotic 80-03-5 C14H14N2O4S Acedoben Nootropic 556-08-1 C9H9NO3 Acefluranol Steroid
    [Show full text]
  • Cutting-Edge Organic Synthesis and Chemical Biology of Bioactive Molecules Yuichi Kobayashi Editor
    Cutting-Edge Organic Synthesis and Chemical Biology of Bioactive Molecules Yuichi Kobayashi Editor Cutting-Edge Organic Synthesis and Chemical Biology of Bioactive Molecules The Shape of Organic Synthesis to Come Editor Yuichi Kobayashi Department of Biotechnology Tokyo Institute of Technology Yokohama, Japan ISBN 978-981-13-6243-9 ISBN 978-981-13-6244-6 (eBook) https://doi.org/10.1007/978-981-13-6244-6 © Springer Nature Singapore Pte Ltd. 2019 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. This Springer imprint is published by the registered company Springer Nature Singapore Pte Ltd.
    [Show full text]
  • Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for GERD / Esophageal Reflux
    Dr.
    [Show full text]